An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Prednisone
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 09 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 09 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 27 Mar 2019 Planned number of patients changed from 55 to 56.